Last reviewed · How we verify

NCT06941506

Using SPOZ Technology to Support and Enhance the Vitality Acupunch (VA) Exercise Program for Older Adults With Dementia

Completed NA Last updated 24 December 2025
What this trial tests

NA trial testing VA-SPOZ exercise program in Cognitive and Behavioral Impairment in 142 participants. Completed in 18 December 2025.

Timeline
23 April 2025
Primary endpoint
18 December 2025
18 December 2025

Quick facts

Lead sponsorKaohsiung Medical University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment142
Start date23 April 2025
Primary completion18 December 2025
Estimated completion18 December 2025
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Kaohsiung Medical University

Who can join

Adults 65 to 100, any sex, with Cognitive and Behavioral Impairment or Sensory and Perceptual Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project was aimed to examine the effects of a six-month VA exercise program incorporate the SPOZ technology in improving the cognitive behavioral impairment and sensory perceptual impairment of older adults with dementia in adult daycare centers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of VA-SPOZ exercise program

Trials testing the same drug.

Other recruiting trials for Cognitive and Behavioral Impairment

Currently open trials in the same condition.

Other Kaohsiung Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06941506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing